Skip to content
CancerIndex

Publication

Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease.

Fleur Kleiburg, Linda Heijmen, Annemieke Witteveen, Kiki van Duuren, Paul Zuidgeest, Frits Smit, Lioe-Fee de Geus-Oei, Tom van der Hulle

European radiologySep 16, 2026PMID 42749930doi:10.1007/s00330-026-12875-z Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 18, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260918-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

BACKGROUND: Traditional metastatic burden classifications in metastatic hormone-sensitive prostate cancer (mHSPC) rely on conventional imaging using CHAARTED criteria. As PSMA PET/CT is increasingly used for staging, revised definitions of low-volume (LVD) and high-volume disease (HVD) are needed…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.